메뉴 건너뛰기




Volumn 46, Issue 5, 2015, Pages 542-549

Experience with aflibercept for the treatment of neovascular age-related macular degeneration

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

EID: 84930420653     PISSN: 23258160     EISSN: 23258179     Source Type: Journal    
DOI: 10.3928/23258160-20150521-05     Document Type: Article
Times cited : (7)

References (21)
  • 1
    • 84870723704 scopus 로고    scopus 로고
    • Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
    • Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548.
    • (2012) Ophthalmology , vol.119 , Issue.12 , pp. 2537-2548
    • Heier, J.S.1    Brown, D.M.2    Chong, V.3
  • 2
    • 33749445317 scopus 로고    scopus 로고
    • Ranibizumab for neovascular age-related macular degeneration
    • Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
    • (2006) N Engl J Med , vol.355 , Issue.14 , pp. 1419-1431
    • Rosenfeld, P.J.1    Brown, D.M.2    Heier, J.S.3
  • 3
    • 33749451356 scopus 로고    scopus 로고
    • Ranibizumab versus verteporfin for neovascular age-related macular degeneration
    • Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
    • (2006) N Engl J Med , vol.355 , Issue.14 , pp. 1432-1444
    • Brown, D.M.1    Kaiser, P.K.2    Michels, M.3
  • 4
    • 84866370357 scopus 로고    scopus 로고
    • Aflibercept for age-related macular degeneration: A game-changer or quiet addition?
    • Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. Aflibercept for age-related macular degeneration: A game-changer or quiet addition? Am J Ophthalmol. 2012;154(2):222-226.
    • (2012) Am J Ophthalmol , vol.154 , Issue.2 , pp. 222-226
    • Browning, D.J.1    Kaiser, P.K.2    Rosenfeld, P.J.3    Stewart, M.W.4
  • 5
    • 84857250733 scopus 로고    scopus 로고
    • Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration
    • Ohr M, Kaiser PK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother. 2012;13(4):585-591.
    • (2012) Expert Opin Pharmacother , vol.13 , Issue.4 , pp. 585-591
    • Ohr, M.1    Kaiser, P.K.2
  • 6
    • 84879235232 scopus 로고    scopus 로고
    • Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
    • e11
    • Bakall B, Folk JC, Boldt HC, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol. 2013;156(1):15-22 e11.
    • (2013) Am J Ophthalmol , vol.156 , Issue.1 , pp. 15-22
    • Bakall, B.1    Folk, J.C.2    Boldt, H.C.3
  • 7
    • 84879209123 scopus 로고    scopus 로고
    • Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors
    • e22
    • Ho VY, Yeh S, Olsen TW, et al. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol. 2013;156(1):23-28 e22.
    • (2013) Am J Ophthalmol , vol.156 , Issue.1 , pp. 23-28
    • Ho, V.Y.1    Yeh, S.2    Olsen, T.W.3
  • 8
    • 84879203732 scopus 로고    scopus 로고
    • Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration
    • e22
    • Yonekawa Y, Andreoli C, Miller JB, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol. 2013;156(1):29-35 e22.
    • (2013) Am J Ophthalmol , vol.156 , Issue.1 , pp. 29-35
    • Yonekawa, Y.1    Andreoli, C.2    Miller, J.B.3
  • 9
    • 0030793930 scopus 로고    scopus 로고
    • Proper method for calculating average visual acuity
    • Holladay JT. Proper method for calculating average visual acuity. J Refract Surg. 1997;13(4):388-391.
    • (1997) J Refract Surg , vol.13 , Issue.4 , pp. 388-391
    • Holladay, J.T.1
  • 10
    • 84883740682 scopus 로고    scopus 로고
    • Visual and anatomical autcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration
    • Kumar N, Marsiglia M, Mrejen S, et al. Visual and anatomical autcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina. 2013;33(8):1605- 1612.
    • (2013) Retina , vol.33 , Issue.8 , pp. 1605-1612
    • Kumar, N.1    Marsiglia, M.2    Mrejen, S.3
  • 11
    • 67149101784 scopus 로고    scopus 로고
    • A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: Year 2 of the PrONTO Study
    • e41
    • Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148(1):43-58 e41.
    • (2009) Am J Ophthalmol , vol.148 , Issue.1 , pp. 43-58
    • Lalwani, G.A.1    Rosenfeld, P.J.2    Fung, A.E.3
  • 12
    • 79953295148 scopus 로고    scopus 로고
    • Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: The SUSTAIN study
    • Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: The SUSTAIN study. Ophthalmology. 2011;118(4):663- 671.
    • (2011) Ophthalmology , vol.118 , Issue.4 , pp. 663-671
    • Holz, F.G.1    Amoaku, W.2    Donate, J.3
  • 13
    • 84887150456 scopus 로고    scopus 로고
    • Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP)
    • Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292-2299.
    • (2013) Ophthalmology , vol.120 , Issue.11 , pp. 2292-2299
    • Rofagha, S.1    Bhisitkul, R.B.2    Boyer, D.S.3    Sadda, S.R.4    Zhang, K.5
  • 14
    • 84863327423 scopus 로고    scopus 로고
    • Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial
    • Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399-1411.
    • (2012) Ophthalmology , vol.119 , Issue.7 , pp. 1399-1411
    • Chakravarthy, U.1    Harding, S.P.2    Rogers, C.A.3
  • 15
    • 84863320414 scopus 로고    scopus 로고
    • Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results
    • Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology. 2012;119(7):1388-1398.
    • (2012) Ophthalmology , vol.119 , Issue.7 , pp. 1388-1398
    • Martin, D.F.1    Maguire, M.G.2    Fine, S.L.3
  • 16
    • 79956218863 scopus 로고    scopus 로고
    • Ranibizumab and bevacizumab for neovascular age-related macular degeneration
    • Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
    • (2011) N Engl J Med , vol.364 , Issue.20 , pp. 1897-1908
    • Martin, D.F.1    Maguire, M.G.2    Ying, G.S.3
  • 17
    • 74549137478 scopus 로고    scopus 로고
    • Ranibizumab (Lucentis) in neovascular age-related macular degeneration: Evidence from clinical trials
    • Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol. 2010;94(1):2-13.
    • (2010) Br J Ophthalmol , vol.94 , Issue.1 , pp. 2-13
    • Mitchell, P.1    Korobelnik, J.F.2    Lanzetta, P.3
  • 18
    • 33645331188 scopus 로고    scopus 로고
    • Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration
    • e1
    • Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(4):623-632.e1.
    • (2006) Ophthalmology , vol.113 , Issue.4 , pp. 623-632
    • Rosenfeld, P.J.1    Heier, J.S.2    Hantsbarger, G.3    Shams, N.4
  • 19
    • 84886430519 scopus 로고    scopus 로고
    • Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
    • Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258-1267.
    • (2013) Lancet , vol.382 , Issue.9900 , pp. 1258-1267
    • Chakravarthy, U.1    Harding, S.P.2    Rogers, C.A.3
  • 20
    • 84930427881 scopus 로고    scopus 로고
    • Center for Drug Evaluation and Research
    • Center for Drug Evaluation and Research. Eylea Label. 2013. Report No. 125387Orig1s000.
    • (2013) Eylea Label


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.